High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 - Concepedia

Concepedia

Publication | Closed Access

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

915

Citations

13

References

2000

Year

John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak, Jon Richards, Lawrence E. Flaherty, Marc S. Ernstoff, Thomas J. Smith, Uma Rao, Mary Steele, Ronald H. Blum

Journal of Clinical Oncology

Abstract

The results of the intergroup E1690 trial demonstrate an RFS benefit of IFNalpha2b that is dose-dependent and significant for HDI by Cox multivariable analysis.

References

	Year	Citations
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J M Kirkwood, M H Strawderman, Marc S. Ernstoff, Journal of Clinical Oncology	1996	2.1K
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression W. H. Clark, David E. Elder, DuPont Guerry, JNCI Journal of the National Cancer Institute	1989	1.2K
A Multifactorial Analysis of Melanoma Charles M. Balch, Tariq M. Murad, Seng‐Jaw Soong, Annals of Surgery	1978	574
Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases Jean‐Jacques Grob, Brigitte Dréno, Pauline de La Salmonière, The Lancet Surgical OncologyDetectable Node MetastasesMedicineMelanomaImmunology	1998	435
A Multifactorial Analysis of Melanoma Charles M. Balch, Seng‐Jaw Soong, Tariq M. Murad, Annals of Surgery	1981	367
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. Hubert Pehamberger, H. Peter Soyer, Andreas Steiner, Journal of Clinical Oncology	1998	360
A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia Charles M. Balch, Seng‐Jaw Soong, G. W. Milton, Annals of Surgery Prognostic FactorsSurgical OncologyNode DissectionCancer ManagementEpidemiology Of Cancer	1982	351
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. Antônio C. Buzaid, Merrick I. Ross, Charles M. Balch, Journal of Clinical Oncology	1997	302
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. Edward T. Creagan, Robert J. Dalton, David L. Ahmann, Journal of Clinical Oncology	1995	251
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. Bernard F. Cole, Richard D. Gelber, J M Kirkwood, Journal of Clinical Oncology	1996	205

Page 1